NEW YORK, NY (Marketwire – May 15, 2012)
World-renowned prostate surgeon, Dr. David Samadi, may soon have the equation he needs to strengthen his approach to personalized medicine and prostate cancer treatment. Researchers at the University of Pittsburgh School of Medicine developed a new prostate cancer diagnostic formula to accurately predict the lifecycle of a man’s prostate cancer.
Beyond confirming the presence of prostate cancer, this new test gives unprecedented insight into the cancer’s aggressiveness and the likelihood of relapse after treatment. By conducting genetic analysis of copy number variations (CNV) in the tumor cells, the cells of the surrounding benign tissue, and the blood cells, experts were able to predict the prostate cancer’s path with as much as 81 percent accuracy.
“This may be the magic mix we need to fully understand prostate cancer once it’s diagnosed,” expressed Dr. Samadi. “Being able to unlock the aggressiveness of each unique diagnosis and then tailor surgery and other treatments accordingly will elevate how we eradicate prostate cancer exponentially.”
The prostate specific antigen (PSA) blood test and follow-up biopsy receive ongoing scrutiny for their diagnostic limitations. Despite even the government poking holes in these tests, Dr. Samadi remains a steadfast proponent of their effectiveness. “The PSA test and the biopsy are the best prostate cancer indicators we have today,” said Dr. Samadi. “As an expert, my job is to educate men about their disease and offer the most personalized and effective care possible.”
As Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center, Dr. Samadi’s robotic prostate removal surgery is one of the most effective prostate cancer treatment options available. Using his custom SMART (Samadi Modified Advanced Robotic Technique) surgery he has successfully removed over 4,000 cancerous prostates.
While his results are impressive — 96% of his patients regain continence and 85% regain sexual function with proper follow-up care — Dr. Samadi’s focus remains on the patients and their families.
“Personalized medicine is a buzz phrase right now,” he admits, “but it’s truly the way my staff and I have approached patients for years. The possibility of this new CNV analysis will revolutionize how we tailor the treatment and care of each patient.”
Dr. Samadi’s staff expertly manages all aspects of patient coordination before each prostate surgery, for both domestic and international patients. During the surgery itself, one team is consistently present and Dr. Samadi performs the entire procedure himself. In the weeks and months following surgery, he works closely with men and their partners to ensure restoration of quality of life and a zero PSA.
After further testing, this first-of-its-kind CNV test could have a major impact on the confidence with which men and their specialists make prostate cancer treatment choices as early as 2015.Press Release